https://www.live-feeds.com/feed/fda-orders-new-warning-on-ozempic-wegovy-other-glp-1-drugs-over-rare-eye-conditionContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-orders-new-warning-on-ozempic-wegovy-other-glp-1-drugs-over-rare-eye-conditionhttps://www.live-feeds.com/feed/fda-orders-new-warning-on-ozempic-wegovy-other-glp-1-drugs-over-rare-eye-condition#u198776Fri, 13 Nov 2026 13:00:18 +0000Federal health regulators directed manufacturers of popular GLP-1 receptor agonist medications to include new product warnings regarding a rare eye condition linked to sudden blindness. The regulatory action targets widely prescribed diabetes and weight loss drugs including Ozempic, Wegovy, and Zepbound. Patients and healthcare providers are advised to monitor for potential vision loss risks associated with the treatments. The Food and Drug Administration issued the mandates following safety reviews concerning the class of drugs. Additional details regarding implementation timelines and specif